Auspex Pharma nails down $25M in D round; Merck gets standard FDA review for sleep drug;

Conversations on Twitter :

 @FierceBiotech: After cashing in on life-saving boast, biotech stayed mum on patient death. Story | Follow @FierceBiotech

 @JohnCFierce: Catalyst $CPRX cocaine addiction drug flops in phase IIb, shares down 65%--a penny stock now. More | Follow @JohnCFierce

 @RyanMFierce: GNS Healthcare, Mt. Sinai and Farber want to drop a Big Data bomb on cancer with a computer model of mult. myeloma. Release | Follow @RyanMFierce

> Auspex Pharmaceuticals in La Jolla, CA, which plans to enter late-stage development with a lead compound for Huntington's disease, has reeled in $25 million from a Series D round of financing with lead backer Panorama Capital joined by Thomas, McNerney & Partners, CMEA Capital and Sloan Biotech Fund. Release

> The Belgian biotech Galapagos revealed evidence of safety and efficacy from a Phase IIa study of its JAK1 inhibitor GLPG0634 in patients with rheumatoid arthritis. News

> The FDA has granted Merck ($MRK) a standard review for its experimental sleep drug, suvorexant, and accepted the company's New Drug Application. Release

> Nimbus Discovery and Proteros Biostructures have joined forces in a partnership for drug discovery. Item

Pharma News

@FiercePharma: Will Merck's Oxytrol benefit from new FDA interest in OTC access? More | Follow @FiercePharma

> GSK, XenoPort part ways after Horizant disappointment. Article

> Sun joins dermatology rush with $230M Dusa buyout. News

> Long-term study reinforces safety record of blockbuster Pradaxa. Story

Medical Device News

 @FierceMedDev: Theragenics faced slumping revenue in Q3. The device maker blames hc reform, the device tax and economic uncertainty. More | Follow @FierceMedDev

 @MarkHFierce: OraSure's new HIV rapid Dx test helped reduce losses in Q3. News | Follow @MarkHFierce

 @DamianFierce: Boston Sci is now a hypertension player, spending $425M on Vessix, a Fierce 15 winner. More | Follow @DamianFierce

> GenMark's revenue soars as loss narrows. News

> Bausch + Lomb snatches up ophthalmology laser startup. Item

Vaccine News

 @AlisonBFierce: The percentage of drug-resistant malaria cases is on the rise in Southeast Asia, a cause for concern among experts. News | Follow @AlisonBFierce

> GSK withdraws infant vaccine in Canada. Article

> BiondVax, MonoSol Rx develop oral universal flu vaccine. News

> Scripps researchers develop methamphetamine vaccine. Story

> PsiOxus lands $2.7M for ovarian cancer vaccine trial. Item

Pharma Manufacturing News

> African raids seize 82M doses of counterfeits. Report

> Another online seller of fake Viagra heads for jail. Story

> Hospira slowly ramps up production. Article

> GlaxoSmithKline pulls vaccines after bacteria found in plant. News

And Finally… Signs of baldness are markers for heart disease, researchers report. Article

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

ATAI Life Sciences is topping off a busy year with a $125 million financing, which will push two programs through phase 2 readouts.

After more than a decade working on heart failure programs with Cytokinetics, Amgen is handing two programs back to its partner.